Ascendis Pharma A/S announced that YORVIPATH®? (palopegteriparatide, developed as TransCon PTH), a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism, is now available in Germany and Austria. YORVIPATH is the second product developed with Ascendis Pharma's TransCon technology platform to be launched commercially.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
133.5 USD | +0.25% | -2.73% | +5.96% |
May. 10 | Paycom Software Insider Sold Shares Worth $503,551, According to a Recent SEC Filing | MT |
May. 06 | European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.96% | 7.62B | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- ASND Stock
- News Ascendis Pharma A/S
- Ascendis Pharma A/S Launches 2nd TransCon Product: YORVIPATH Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism